FGL Peptide | Brain Repair & Cognitive Support

Overview

FGL demonstrates specific binding affinity for NCAM receptors and associated co-receptors, contributing to its unique neuroprotective profile. The peptide is metabolized primarily in the liver with partial renal elimination, and shows excellent CNS penetration with sustained bioavailability up to 24 hours post-administration using specialized detection methods.

Chemical structure & Properties

• Molecular Formula: Specific sequence derived from NCAM fibronectin type III domain

• Molecular Weight: Approximately 1,500-2,000 Da (varies by specific FGL variant)

• Sequence: Peptide derived from neural cell adhesion molecule fibronectin domain

• Half-life: 4-6 hours following subcutaneous administration

• Stability: Enhanced resistance to proteolytic degradation

Regulatory Status and

Legal Considerations

FDA Status

• Classification: Research peptide, not approved for therapeutic use

• Approval Status: Not approved for human therapeutic use

• Development Stage: Preclinical development with limited human data

• Regulatory Position: Phase I human studies needed for safety determination

WADA Status

• Classification: Potentially prohibited under cognitive enhancement regulations

• Athletic Use: Status unclear for competitive sports

• Testing: Limited detection methods available

Legal Availability

• Commercial Status: Not legally available as prescription medication

• Market Presence: Available as "research chemicals" through specialized providers

• Quality Control: Variable quality and purity from different suppliers

• Clinical Use: Limited to research settings and experimental protocols

The Paragon Method: Step-by-Step

Clinical Considerations

Important Notes:

• No FDA-approved dosing guidelines exist for human use

• Individual response may vary significantly

• Medical supervision recommended for any therapeutic application

• Quality and purity of commercially available products not guaranteed

Priority Research Areas

• Large-scale human clinical trials for safety and efficacy determination

• Standardized dosing protocols for cognitive enhancement applications

• Long-term safety studies including neurological monitoring

• Mechanism elucidation of NCAM-mediated pathways

• Comparative effectiveness studies against established cognitive enhancers

Emerging Applications

Research is investigating potential applications in:

• Alzheimer's disease and neurodegenerative conditions

• Traumatic brain injury recovery and rehabilitation

• Age-related cognitive decline prevention

• Learning disabilities and attention disorders

• Athletic performance and cognitive optimization

Conclusion

FGL represents a promising neuroprotective peptide with demonstrated benefits in preclinical models of cognitive enhancement, synaptic plasticity, and neuronal protection. Its unique mechanism of action through NCAM-mediated signaling offers potential advantages in neurological applications and cognitive medicine. However, the current evidence base remains predominantly preclinical, with limited human clinical data available.

The lack of FDA approval, potential safety considerations, and regulatory restrictions necessitate careful consideration and medical supervision for any therapeutic application. Patients interested in FGL therapy should engage in thorough discussions with qualified healthcare providers to weigh potential benefits against risks and explore evidence-based treatment alternatives.

Future research will be critical in establishing the safety, efficacy, and appropriate clinical applications of FGL in human medicine. Until comprehensive clinical trials are completed, its use should remain limited to research settings and experimental protocols under appropriate medical oversight.

FGL SCIENTIFIC

DATA SUMMARY

Parameter

Molecular Weight

Amino Acid Length

Half-Life

Bioavailability

Detection Window

Value

1,500-2,000 Da

NCAM-derived peptide

4-6 hours (hepatic)

Excellent CNS penetration

Up to weeks (immune effects)

Application

Cognitive Enhancement

Neuroprotection

Synaptic Plasticity

Neural Repair

Studies

Multiple studies

Preclinical trials

LTP studies

Regeneration models

Dose Range

0.1-10 mg/kg

1-2 mg/dose

Variable dosing

Local application

Outcome

Enhanced LTP, improved memory performance

Protection against amyloid-beta toxicity

Facilitated long-term potentiation

Enhanced axonal regrowth, tissue repair

Study Type

Plasticity Study

Neuroprotection Study

Review Study

Population

Hippocampal models (Dallérac)

Amyloid-beta models (Corbett)

Cognitive enhancers (Asua)

Results

Enhanced synaptic strength

Significant neuronal protection

Cognitive-enhancing properties

Limitations

Preclinical data only

Animal studies, human trials needed

Standardized protocols needed

Parameter

Acute Toxicity

Organ Toxicity

Adverse Events

Long-term Safety

Finding

No toxicity at therapeutic doses

No significant systemic toxicity

Minimal reported in preclinical studies

Limited human data available

Authority

FDA

WADA

DEA

Classification

Research Peptide

Potential Cognitive Enhancer

Unscheduled

Status

Not approved for human use

Status unclear

Not controlled substance

Peptides work best as one part of a complete, medically supervised plan. We build these into a longevity plan guided by testing, including Metabolic Breath Analysis. To see how this fits your goals, explore our full approach to peptide therapy in Atlanta.

Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. FGL is not approved by the FDA for human therapeutic use. Patients should consult with qualified healthcare providers before considering any peptide therapy.

The content reflects current scientific literature and regulatory status as of 2025.

Explore Peptide Therapy at Paragon

Peptides work best as part of a bigger plan, not on their own. At Paragon Sports Medicine in Atlanta, every peptide is prescribed by our team, guided by your labs and your goals, and matched to the right protocol for you. If you are wondering whether this one fits where you want to go, our peptide therapy program in Atlanta is the place to start.